CLINUVEL Gains Health Canada NOC for SCENESSE in Rare Photoprotection Indication

Post-marketing data accumulated across three prior regulatory jurisdictions has now anchored a fourth: CLINUVEL Pharmaceuticals has received a Notice of Compliance (NOC) from Health Canada for SCENESSE® (afamelanotide 16mg implant), authorising its use for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The approval, issued under Sections C.08.002 and C.08.005 of the Canadian Food and Drug Regulations, positions the submission as a working model for leveraging longitudinal post-marketing safety packages in rare disease multi-jurisdictional filings.

The Canadian NOC follows sequential authorisations in Europe (2014), the U.S. (2019), and Australia (2020). CLINUVEL's regulatory submission drew substantially on post-marketing experience accumulated across those markets, where over 21,000 doses have been administered to EPP patients, with the longest-treated individuals receiving continuous therapy for up to 20 years. For QA and regulatory leads managing rare disease portfolios, the evidentiary weight assigned to that longitudinal dataset is the operationally significant detail here.

EPP is a rare metabolic disorder affecting an estimated 1 in 140,000 individuals in Canada, characterised by debilitating phototoxic reactions following brief exposure to visible light. SCENESSE® delivers its photoprotective effect by stimulating melanin production via afamelanotide, an analogue of alpha-melanocyte-stimulating hormone, administered as a subcutaneous implant in accredited outpatient settings. The drug carries no approved comparator; it remains the only EPP treatment to have received marketing authorisation from any regulatory body worldwide.

Distribution infrastructure was already partially in place ahead of the NOC. Five Specialty Centers in Canada had been trained, accredited, and treating EPP patients under special access arrangements prior to formal approval, a sequencing that compresses the gap between regulatory clearance and patient access. CLINUVEL's broader North American Specialty Center network, established following FDA authorisation in 2019, provides the operational backbone for Canadian commercial rollout.

The most commonly reported adverse events in clinical trials included headache, nausea, implant site reactions, oropharyngeal pain, fatigue, and skin hyperpigmentation; the safety profile has remained consistent across two decades of monitored use. For pharmacovigilance and GMP-compliant distribution teams, the 20-year continuous-use dataset represents an unusually mature post-market safety dossier for a rare disease asset.

The pace at which CLINUVEL converts its five pre-approved Canadian Specialty Centers into active commercial sites will serve as the near-term indicator of whether pre-approval infrastructure investment translates into measurable patient access gains.

Source: CLINUVEL Pharmaceuticals via GlobeNewswire, 13 July 2026.